Lymphoma

Patients with IgG4-related disease are at a higher risk for cancer — particularly pancreatic and lymphoma — compared with the general population, according to a meta-analysis published in Arthritis Research & Therapy.

HF may be associated with cancer incidence as well as risk for cancer-related mortality, especially among individuals aged 50 to 70 years, according to new data published in JACC: CardioOncology.

Gilead Sciences has decided to voluntarily withdraw its accelerated approval of idelalisib for two blood cancer indications.

The FDA granted fast track and regenerative medicine advanced therapy designations to C-CAR039, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory diffuse large B cell lymphoma.

The FDA lifted its clinical hold on a series of trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer.

Older patients with B-cell malignancies diagnosed with COVID-19 had a substantially higher risk for death than their counterparts aged 60 years or younger, according to study results published in JCO Oncology Practice.

A chimeric antigen receptor T-cell therapy induced high response rates across a range of B-cell malignancies, according to phase 1 study results presented at ASH Annual Meeting and Exposition.

Fully vaccinated patients with cancer who developed breakthrough COVID-19 infections appeared at high risk for hospitalization and death, according to study results published in Annals of Oncology.

Patients with blood cancer appeared at greater risk for severe and life-threatening COVID-19 illness than healthy individuals and did not always achieve optimal protection from vaccination, according to a registry-based study in Blood.

Early clinical trials for the first chimeric antigen receptor T-cell therapies mandated recipients receive rigorous post-treatment monitoring, often requiring inpatient admittance lasting anywhere from 2 to 4 weeks.